| Market Cap | 281.13M | P/E | - | EPS this Y | -23.10% | Ern Qtrly Grth | - |
| Income | -116.49M | Forward P/E | -2.09 | EPS next Y | -9.80% | 50D Avg Chg | -4.00% |
| Sales | 42.51M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -40.00% |
| Dividend | N/A | Price/Book | 1.23 | EPS next 5Y | - | 52W High Chg | -63.00% |
| Recommedations | 1.60 | Quick Ratio | 7.34 | Shares Outstanding | 107.14M | 52W Low Chg | 29.00% |
| Insider Own | 12.93% | ROA | -21.76% | Shares Float | 49.37M | Beta | 0.85 |
| Inst Own | 90.38% | ROE | -50.58% | Shares Shorted/Prior | 10.45M/10.12M | Price | 3.18 |
| Gross Margin | -218.07% | Profit Margin | -274.04% | Avg. Volume | 188,188 | Target Price | 16.13 |
| Oper. Margin | -148.69% | Earnings Date | Nov 6 | Volume | 67,066 | Change | -2.45% |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
| HC Wainwright & Co. | Buy | Sep 10, 24 |
| Wedbush | Outperform | Aug 8, 24 |
| Jefferies | Buy | Jul 17, 24 |
| Cantor Fitzgerald | Overweight | Jul 9, 24 |
| HC Wainwright & Co. | Buy | Jul 9, 24 |
| HC Wainwright & Co. | Buy | May 28, 24 |
| Guggenheim | Buy | May 24, 24 |
| Barclays | Overweight | May 24, 24 |
| Wedbush | Outperform | May 23, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Boxer Capital, LLC | Other Other | Oct 13 | Buy | 6.96 | 1,250,000 | 8,700,000 | 8,198,642 | 10/17/23 |
| Boxer Capital, LLC | Other Other | Oct 09 | Sell | 9.94 | 225,000 | 2,236,500 | 6,948,642 | 10/11/23 |
| Boxer Capital, LLC | Other Other | Aug 11 | Buy | 5.15 | 475,000 | 2,446,250 | 743,542 | 08/15/23 |
| Boxer Capital, LLC | 10% Owner 10% Owner | Oct 11 | Buy | 4.44 | 237,000 | 1,052,280 | 7,123,642 | 10/13/22 |
| Boxer Capital, LLC | 10% Owner 10% Owner | Oct 04 | Buy | 3.87 | 182,000 | 704,340 | 7,053,642 | 10/06/22 |